This study is investigating whether a medication called risedronate can help reduce bone loss after sleeve gastrectomy (a type of weight-loss surgery). Risedronate is already approved to prevent and treat osteoporosis (a condition that makes bones weak) in older adults. Researchers want to see if it can also help people who have had sleeve gastrectomy. You may be able to join if you've had sleeve gastrectomy, are at least 30 years old, and weigh less than 450 lbs. The study will compare risedronate to a placebo (an inactive pill) to see if risedronate can improve bone mineral density in the hip over 6 and 12 months. The current status of this study is unclear.

Study design

This interventional study plans to enroll 200 participants. Participants will be randomly assigned to receive either risedronate or a placebo.

What's involved

Participation will involve up to 6 study visits and last about 1 year. You will complete two visits before starting the intervention.

Compensation

Not stated in the trial record.

Follow-up

Bone mineral density will be measured at baseline, 6 months, and 12 months after the intervention begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.